Fundraising FoxIQ Capital — 2025 Investments
5 investments dated 2025 · listed companies and verified rows first · show all
AiM Medical Robotics develops a portable, MRI-compatible surgical robot for neurosurgical procedures performed in the MRI suite and operating room, aimed at improving precision and automation for treating functional brain disorders (such as Parkinson's and epilepsy) and cancer.
HealthtechMedical DevicesRoboticsWorcester, US
Gregory Fischer(CEO/President, Founder & Co-inventor)inJulie G. Pilitsis(Chair of Medical Advisory Board, Founder & Co-Inventor)Andrew Aberdale(President & Chief Financial Officer)inRachel LeBlanc(Chief Operations Officer & Board Secretary)inCraig Pierson(Director, Promoter)in
BoardRobert Cathcart(Chairman)
Co-investorsSymbiotic Ventures
IONATE develops smart transformer hardware and AI coordination software for power systems and grids, designed to modernize electricity infrastructure for data centers and grid applications.
AI & Machine LearningEnergyHardwareLondon, GB
Luca(CGO)inAdhikari Ajanta(Executive Officer, Director)in
Co-investorsAlbionVCGlobal BrainIn-Q-TelZero Carbon CapitalZero Carbon CapitalAntares Ventures Pte. Ltd.+1 more
Synthesized creates governed, production-realistic test data from sensitive enterprise systems for software validation, migrations, and AI-agent testing.
AI & Machine LearningData & InfrastructureEnterprise Software
Co-investorsDeutsche BankExpeditionsFounders FactoryFounders Factory NYIA Seed VenturesMundi Ventures+3 more
Tolerance is a compliance platform that runs continuous automated checks against the NIST 800-171 standard and collects assessor-ready evidence for teams handling Controlled Unclassified Information (CUI).
CybersecurityGovTechSaaS
Co-investorsDorm RoomAmadeus Capital PartnersBen Franklin Technology PartnersBioAdvanceColumbus Venture PartnersCriteria Bio Ventures+5 more
Trogenix develops precision gene therapies for cancer using its Odysseus platform and Synthetic Super-Enhancer (SSE) technology, engineered DNA elements activated only in diseased cell states to selectively target and kill tumour cells while activating the immune system.
AI & Machine LearningBiotechDeep TechHealthtechMedical DevicesEdinburgh, GB
Ken Macnamarain
Co-investorsACADEMY INVESTORAIN VenturesCalculus Capital Ltd.LongeVCOld College Capital4BIO Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.